Tag Archives | momentum stocks

Sluggish Biotech Stocks: Five Underlying Factors Plus A Sector Shift?

MegaCap Tech Stocks Take a Big Hit-Volatility Rising in a Sector Shift Market Rotation Supports Overall Market-S&P 500 Stable today up 17% YTD Sluggish Biotech Now Just a Market Performer With IBB up 17% YTD The booming tech sector sold off today with the XLK down over 2%. Harder hit were the 2017 high fliers […]

Continue Reading 0

Biotech Hangover: Recent Earnings Feed Caution with No Near Term Catalysts

Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we posted that Risks were Rising for the 2017 biotech rally primarily because technicals were weakening […]

Continue Reading 0

Rayno BioBeat #6: What Have I Missed After Two Weeks of Travel and Away From Trading Biotech Stocks?…Update 11/3

BioBeat Market Update…Technicals Firming Up 11/3/17 11am A lot of green screen today so time to nibble but I would prefer to pick stocks rather than play the ETF game. Recent trades we made are: sell XBI at $87, buy PFE at $35 and today buy CELG at $100. No change in our Biopharmaceutical Portfolio […]

Continue Reading 0

Risks Rising for Rally: Political Rhetoric Tempers Bulls

Risks Rising for Healthcare Sector As Harsh Political Rhetoric Returns Trump returns to drug pricing attacks. Healthcare sector lags. Opioid crisis blames drug distribution companies for easy access. Sector on hold awaiting Q3 earnings: XLV down 0.44% today near its 52 week high. The early rally in biotech and drug stocks reversed on the 10 […]

Continue Reading 0

Rayno BioBeat #4: Biotechs Weaken on Profit Taking…Update-2

Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and suggested last week […]

Continue Reading 0

ACA: Uncertainty Remains After Healthcare Bill Failure But Stocks Get a Second Wind…Update-1

Update-1… JY 19…Biotech and Healthcare Stocks Continue to Rally IBB breaks through top to $322.92 up 21.68% YTD; XBI up 1.34% today 35.4% YTD; XLV up 17.6% YTD. Rayno Life Science top winners YTD: ABBV up 18.19%, AMGN up 22.6%, BLUE up 55% YTD, FMI up 114.7%, RHHBY up 12.86%. All beating the S&P. BMY […]

Continue Reading 0

Biotech Avoids Tech Wreck of June 9…Update-2 June 15

June 15-Update 2 after close…Biotechs Down with Techs-Red Screen Day Very few winners today: IBB down 0.77%, XBI down 1.36% to $71.55 near 52 week high of $73. ABBV near new highs at $70.60, BLUE up 24.7% for past month. EPZM soars 17% on EZH2 inhibitor, RXDX up 5.8% continues run on NTRK inhibitor. Trump Executive […]

Continue Reading 0

Biotech Fades After ASCO Abstract Rally

Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone?  Technicals Matter  Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ retained momentum with the ETF leader QQQ up 19% YTD pulling ahead of the biotech ETFs. Large cap tech stocks rule. The large cap centric […]

Continue Reading 0

Biotechs Running Again: Rayno Life Science Stocks-See Picks…Earnings Updates

Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for EPS was confirmed at $5.44-5.54. Stock closed up 1.55% today to $66.05. Alexion […]

Continue Reading 0

Biotech Bear Market Looking For Relief From Q3 Large Cap Growth…Update-3

Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson (MCK). All large caps are red except Alexion (ALXN) up 1.83%. Abbvie (ABBV) down 6% on revenue miss;Humira […]

Continue Reading 0